Sernova Biotherapeutics Inc · TSX:SVA

Sernova Biotherapeutics — Sernova — Investor Presentation (September 2023)

27 slides from Sernova Biotherapeutics's investor presentation, September 2023

  1. Slide 1: Advancing cell therapeutics to provide 'functional cures'

    Slide 1: Advancing cell therapeutics to provide 'functional cures'

    June 2023 Advancing cell therapeutics to provide ‘functional cures’ September 2023

  2. Slide 2: Sernova Corp. Forward Looking Statements

    Slide 2: Sernova Corp. Forward Looking Statements

    Sernova Corp. Forward Looking Statements This presentation contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements in this presentation are statements that are not historical facts and are generally, but not always, identified by the

  3. Slide 3: Sernova Corp is a clinical-stage company developing 'functional cures'

    Slide 3: Sernova Corp is a clinical-stage company developing 'functional cures'

    Sernova Corp is a clinical-stage company developing ‘functional cures’ for chronic debilitating diseases. Company’s proprietary Cell Pouch System™ consists of an implantable device containing immuno-protected therapeutic cells which sustainably produce missing therapeutic proteins or hormones. Serno

  4. Slide 4: Advancing Cell Therapeutics for Functional Cures

    Slide 4: Advancing Cell Therapeutics for Functional Cures

    Advancing Cell Therapeutics for Functional Cures Pipeline of multiple cell therapies combined with Cell Pouch System for chronic diseases . Cell Pouch System establishes an organ-like environment for all cell-based therapies Proof of concept established in patients with Type 1 Diabetes (T1D) – Addit

  5. Slide 5: Advantages of Pancreatic Islet Cell Therapy vs. Insulin Injection

    Slide 5: Advantages of Pancreatic Islet Cell Therapy vs. Insulin Injection

    Advantages of Pancreatic Islet Cell Therapy vs. Insulin Injection Islets Pancreatic Islets • Clusters of specialized cells responsible for global regulation of blood glucose Pancreas • In T1D a patient’s islets become dysfunctional requiring daily insulin injections Insulin Injections Only provide o

  6. Slide 6: Cell Pouch System Provides Organ-Like Environment

    Slide 6: Cell Pouch System Provides Organ-Like Environment

    Cell Pouch System Provides Organ-Like Environment Creates vascularized tissue chambers to allow optimal engraftment of therapeutic cells Cell Pouch is placed deep under Therapeutic cells are transplanted Therapeutic cells are responsive the skin in a short procedure into the vascularized tissue to e

  7. Slide 7: Product Innovation for Functional Cure in T1D

    Slide 7: Product Innovation for Functional Cure in T1D

    Product Innovation for Functional Cure in T1D Portfolio built to expand the treatable patient population with successive product generations 1st Generation 2nd Generation 3rd Generation Phase 1/2 Ongoing Phase 1/2 in 2024 Preclinical Ongoing Cell Pouch Cell Pouch “Off the Shelf” Intra-Pouch Cell Pou

  8. Slide 8: Large Addressable Market for a Functional Cure in T1D

    Slide 8: Large Addressable Market for a Functional Cure in T1D

    Large Addressable Market for a Functional Cure in T1D A cell therapy that could eliminate daily insulin injections and provide tighter blood sugar control would command favorable pricing given the high patient burden and comorbidities of T1D United States T1D Population1 Payor survey supports potent

  9. Slide 9: Phase 1/2 Program for T1D Donor Islets + Cell Pouch

    Slide 9: Phase 1/2 Program for T1D Donor Islets + Cell Pouch

    Phase 1/2 Program for T1D Donor Islets + Cell Pouch After completing the safety, tolerability and efficacy study of Sernova's Cell Pouch for clinical islet transplantation and as the first transplant candidate, I can easily state how absolutely wonderful life is to be free of always thinking of how

  10. Slide 10: Phase 1/2 Study Design – First Cohort

    Slide 10: Phase 1/2 Study Design – First Cohort

    Phase 1/2 Study Design – First Cohort Patients with Type 1 Diabetes and Hypoglycemia Unawareness • Open label, single-arm, single-center trial (n=6) • Cell Pouch implant followed by two sequential human donor islet transplants into Cell Pouch • 3 weeks after Cell Pouch implantation, immunosuppressio

  11. Slide 11: Phase 1/2 Interim Update – 5 Patients Achieved 100% Insulin Independence

    Slide 11: Phase 1/2 Interim Update – 5 Patients Achieved 100% Insulin Independence

    Phase 1/2 Interim Update – 5 Patients Achieved 100% Insulin Independence As presented at ADA Conference June 24, 2023 Surgical implantation of the Cell Pouch was found to be well tolerated with a favorable safety profile 5 of 5 patients have achieved complete insulin independence – and a 6th has rec

  12. Slide 12: Phase 1/2 Study Design – 2nd Cohort

    Slide 12: Phase 1/2 Study Design – 2nd Cohort

    Phase 1/2 Study Design – 2nd Cohort >50% more capacity (10 channel) Cell Pouch for dosing & density optimization • Up to 7 additional patients will be enrolled; inclusion/exclusion criteria same as First Cohort • Higher capacity 10-channel Cell Pouch accommodates optimal dose and concentration of tr

  13. Slide 13: 2nd Cohort – Favourable First Clinical Update

    Slide 13: 2nd Cohort – Favourable First Clinical Update

    2nd Cohort – Favourable First Clinical Update Higher capacity allows for higher dosing and reduced time to 2nd transplant • Patient enrollment with implantation commenced November 2022 • 5 patients enrolled and implanted with higher capacity 10 channel Cell Pouches – 3 patients have received first i

  14. Slide 14: Sernova / Evotec Partnership

    Slide 14: Sernova / Evotec Partnership

    Sernova / Evotec Partnership iPSC-Derived Islet-Like Clusters (ILCs)

  15. Slide 15: Sernova / Evotec Partnership

    Slide 15: Sernova / Evotec Partnership

    Sernova / Evotec Partnership Abundant supply of iPSC-derived insulin-producing ILCs for T1D Announced May 2022 • Sernova has option for exclusive global license for Evotec’s ethically derived iPSC insulin producing ILCs for use with Sernova’s Cell Pouch System either alone or with other technologies

  16. Slide 16: Major Advantages Over Competing Approaches

    Slide 16: Major Advantages Over Competing Approaches

    Major Advantages Over Competing Approaches ILCs Novel cell therapy for potential ‘functional cure’ for T1D that is commercially viable at scale Preclinical Commercial • ILCs demonstrated sustained • iPSC-derived stable islet like clusters – provides virtually unlimited supply normalization of blood

  17. Slide 17: iPSC-Islet Like Clusters (ILCs) with Long-Term Antidiabetic Efficacy

    Slide 17: iPSC-Islet Like Clusters (ILCs) with Long-Term Antidiabetic Efficacy

    iPSC- Islet Like Clusters (ILCs) with Long-Term Antidiabetic Efficacy Robust, durable normalization of glucose control in diabetic mice Evotec GMP manufacturing Efficient normalization of random fed glucose by kidney site near Modena/Italy capsule-implanted ILCs Circulating C-peptide • Scalable, GMP

  18. Slide 18: Excellent Anti-diabetic Activity of ILCs in the Cell Pouch

    Slide 18: Excellent Anti-diabetic Activity of ILCs in the Cell Pouch

    Excellent Anti-diabetic Activity of ILCs in the Cell Pouch Rapid normalization of glucose control with human islet-like potency Efficient normalization of random fed glucose Robust circulating hC- peptide levels Efficient glucose mouse glucose setpoint clearance and no hypoglycemias in oGTT (8 week

  19. Slide 19: High β-cell Fraction and Dense Vascularization of ILCs in the Cell Pouch

    Slide 19: High β-cell Fraction and Dense Vascularization of ILCs in the Cell Pouch

    High β-cell Fraction and Dense Vascularization of ILCs in the Cell Pouch Histological graft analysis – 32 weeks post-implantation INS • Abundant endocrine cells with high GCG beta cell fraction detectable SST DAPI − Alpha and delta cells are observed at lower frequencies INS CD31 DAPI INS • ILC cell

  20. Slide 20: Additional Pipeline

    Slide 20: Additional Pipeline

    a Sernova 4, oor Additional Pipeline

  21. Slide 21: Sernova's Conformal Coating Technology: Potential to Eliminate Chronic Immunosuppression Medications

    Slide 21: Sernova's Conformal Coating Technology: Potential to Eliminate Chronic Immunosuppression Medications

    Sernova’s Conformal Coating Technology: Potential to Eliminate Chronic Immunosuppression Medications Sernova holds worldwide exclusive license to technology University of Miami / Sernova Collaboration • Proprietary biocompatible cross-linked polymer hydrogel forms a ‘Shrink wrap’ coating around ther

  22. Slide 22: Cell Pouch System for Thyroid Diseases / Hypothyroidism

    Slide 22: Cell Pouch System for Thyroid Diseases / Hypothyroidism

    Cell Pouch System for Thyroid Diseases / Hypothyroidism One-and-done treatment provides attractive alternative to life-long medications Therapeutic Benefits & Estimated Market 150,000 thyroidectomies performed annually in the US alone Estimated Market $3.6B market opportunity Size First generation p

  23. Slide 23: Cell Pouch System for Hemophilia A

    Slide 23: Cell Pouch System for Hemophilia A

    Cell Pouch System for Hemophilia A Improved safety and durability compared to gene therapy approaches Therapeutic Benefits & Estimated Market Estimated Market 60,000 patients across North America and EU Size $13B in 2021 reaching $27B by 20311 orphan indication Reduce or eliminate factor VIII infusi

  24. Slide 24: Competitive Overview, Upcoming Catalysts & Corporate Information

    Slide 24: Competitive Overview, Upcoming Catalysts & Corporate Information

    Competitive Overview, Upcoming Catalysts & Corporate Information

  25. Slide 25: Selected 2023-2024 Projected Milestones

    Slide 25: Selected 2023-2024 Projected Milestones

    Selected 2023-2024 Projected Milestones Sernova/Evotec iPSC development update at IPITA conference Q2 2023 Phase 1/2 Cohort 1 results update at ADA Q2 2023 2023 Phase 1/2 Cohort 2 patient enrollment update H1 2023 Conformal Coating update Q3 2023 Phase 1/2 Cohort 2 enrollment completion H2 2023 Thyr

  26. Slide 26: Capital Structure / Select Information

    Slide 26: Capital Structure / Select Information

    Capital Structure / Select Information EXCHANGE: 52-week Range 1 $0.69 – $1.28 TSX: SVA Shares Outstanding 303 million OTCQB: SEOVF Market Cap 1 $250 million FSE / XETRA: PSH Average Daily Volume 1,2 115,000 FISCAL Y/E: 10/31 Cash & Equivalents (Q2 4/30/23) $36.8 million $0 Debt Analyst Coverage 1As

  27. Slide 27: TSX: SVA OTCQB: SEOVF FSE / XETRA: PSH

    Slide 27: TSX: SVA OTCQB: SEOVF FSE / XETRA: PSH

    TSX: SVA OTCQB: SEOVF FSE / XETRA: PSH Business Development Investor Relations Modestus Obochi, Ph.D., MBA Head Office Christopher Barnes VP, Investor Relations 1.847.989.1674 700 Collip Circle, Ste 114 modestus.obochi@sernova.com 1.519.902.7923 London, ON, Canada N6G 4X8 christopher.barnes@sernova.

Source: Internet Archive copy of sernova.com

More decks from Sernova Biotherapeutics Inc

All 29 Sernova Biotherapeutics decks